Navigation Links
Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
Date:5/29/2012

SEATTLE, May 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) will host an investor and analyst meeting to discuss unmet medical needs and targeted agents in myelofibrosis and high-risk myelodysplastic syndrome/acute myeloid leukemia, including data from pacritinib, the product candidate that CTI has agreed to acquire, and CTI's product candidate tosedostat. The event will take place on Sunday, June 3, 2012 in Chicago, Illinois.  The American Society of Clinical Oncology Annual Meeting is being held in Chicago from June 1-5, 2012.

Speakers at the event will include: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center, Houston, Texas; Elihu Estey, M.D., Seattle Cancer Care Alliance, Seattle, Wash., Rami Komrokji, M.D., Moffitt Cancer Center, Tampa, Fla.; and David Steensma, M.D., F.A.C.P., Dana-Farber Cancer Institute, Boston, Mass.

The presentations will begin at 7 a.m. CDT /8 a.m. EDT /5 a.m. PDT /2 p.m. CET and conclude at approximately 8 a.m. CDT /9 a.m. EDT /6 a.m. PDT /3 p.m. CET. The presentations will be webcast live with slides and archived at www.celltherapeutics.com.

About Pacritinib

Pacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 (FLT3). Mutations in these kinases have been shown to be directly related to the development of a variety of blood related cancers including MPD, leukemia and lymphoma. Pacritinib has demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis and a phase 3 study is planned in this disease.

FLT3 is a commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome suggesting a possible future role for treatment of AML.

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials.  CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.

About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
2. Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
5. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
6. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
7. Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
8. Nile Therapeutics Reports 2012 First Quarter Financial Results
9. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
10. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
11. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... The COVID-19 ... in March of this year, leadership at SPIRE Institute & Academy (IA) have closely ... and Ohio Governor Mike DeWine’s office to prevent the spread of coronavirus, and keep ...
(Date:5/21/2020)... ... May 21, 2020 , ... Sindledecker Dentistry ... offices had been closed due to the coronavirus pandemic and the practice was ... The office has remained open only for emergency needs and the staff, led ...
(Date:5/21/2020)... Ga. (PRWEB) , ... May 21, 2020 , ... ... RESI (Redefining Early Stage Investments) Conference to offer startup companies a special ... and 10. , The RESI conference series was created by LSN to bring together ...
Breaking Medicine Technology:
(Date:5/15/2020)... Fla. (PRWEB) , ... May 15, 2020 , ... ... Tampa Bay, placed the final beam atop the hospital’s new six-story, 300,000 square ... Ave. and Bruce B. Downs Boulevard. The topping off celebrates the structural completion ...
(Date:5/14/2020)... BAY, Fla. (PRWEB) , ... May 14, 2020 , ... SGF , a premier ... comprehensive suite of fertility procedures and treatment in the Tampa Bay region. , “While this ... the many ways our team members and patients have risen to the occasion. Through the ...
(Date:5/14/2020)... ... May 13, 2020 , ... ... to The Center for Developmental Disabilities. , The vision of the Center for ... in which the following values are embraced: Everyone is treated with dignity and ...
(Date:5/14/2020)... ... 14, 2020 , ... Slone Partners , a nationwide ... placement of Ingo Chakravarty as President and Chief Executive Officer (CEO) of ... after it received Emergency Use Authorization (EUA) from the Federal Drug Administration ...
(Date:5/11/2020)... KENNETT SQUARE, Pa. (PRWEB) , ... May 11, ... ... recent announcement by the Federal Communications Commission (FCC) that it will continue to ... insurance as proof of income eligibility through June 30, 2020. The FCC’s decision ...
Breaking Medicine News(10 mins):